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LEARNING OBJECTIVES
After completing this course, the reader should be able to:
1. Describe the importance of KRAS mutations in CRC patients.
2. Explain the relevance to cancer treatment of concordance of KRAS status between primary tumors and metastases
in CRC patients.
3. Discuss the impact of KRAS mutations as a predictive/prognostic factor in CRC patients.
This article is available for continuing medical education credit at CME.TheOncologist.com.CME
ABSTRACT
Purpose. Several studies have suggested that KRAS so-
matic mutations may predict resistance to cetuximab-
and panitumumab-based treatments in metastatic colo-
rectal cancer (CRC) patients. Nevertheless, most expe-
riences were conducted on samples from primaries. The
aim of this study was to evaluate the grade of concor-
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dance in terms of KRAS status between primaries and
related metastases.
Patients and Methods. We analyzed KRAS codon 12 and
13 mutations from formalin-fixed sections of 107 CRC pri-
maries and related metastases. Eight pairs were excluded
from the analysis because of the low amount of tumor tis-
sue in the available samples. The main characteristics
were: 50 men, 49 women; median age at diagnosis, 71
years (range, 41–84). The metastatic sites analyzed were
the liver in 80 patients (80.8%), lung in seven patients
(7.1%), and other sites in 12 patients (12.1%).
Results. A KRAS mutation was found in 38 (38.4%)
primary tumors and in 36 (36.4%) related metastases.
The rate of concordance was 96.0% (95% confidence in-
terval, 90.0%–98.9%). Discordance was observed in
only four (4%) patients.
Conclusions. Our results indicate that the detection of
KRAS mutations in either primary or metastatic tumors
from patients with CRC is concordant and this assess-
ment could be used to predict response to targeted ther-
apies such as cetuximab and panitumumab. The
Oncologist 2008;13:1270–1275
INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of can-
cer-related death in western countries [1]. Recent therapeu-
tic strategies are based on targeting the epidermal growth
factor receptor (EGFR), which is overexpressed in CRC
[2]. Cetuximab and panitumumab are monoclonal antibod-
ies (mAbs) directed against EGFR. Blockade of EGFR
disrupts downstream signaling pathways such as the phos-
phatidylinositol 3 kinase/Akt, Ras/Raf/mitogen-activated
protein kinase (MAPK), and signal transducer and activator
of transcription pathways, all of which are crucial in the
regulation of cell growth, proliferation, apoptosis, invasion,
migration, and angiogenesis [1]. On the basis of the Bowel
Oncology with Cetuximab Antibody (BOND) trial, cetux-
imab was approved [3] in European countries in combina-
tion with irinotecan for the treatment of patients with
EGFR metastatic CRC who progressed on a prior irinote-
can-based chemotherapy regimen. In subsequent retrospec-
tive analyses, no correlation was found between EGFR
expression assessed by immunohistochemistry (IHC) and
clinical outcome [3, 4]. The need for alternative predictive
factors has become imperative in order to avoid unneces-
sary toxicities and waste of resources.
KRAS mutations occur in about 40% of primary CRCs [5,
6], and such mutations have been demonstrated to be predic-
tors of resistance to anti-EGFR mAbs. In the presence of spe-
cific mutations of the KRAS gene, the Ras protein, which has
intrinsic GTPase activity, is constitutively activated, and sub-
sequent signaling events are unregulated and independent
from EGFR control [7]. Several studies [8–13] in patients with
advanced or metastatic CRC have indicated that the presence
of KRAS mutations (KRAS point mutations in codons 12 and
13) is associated with a lack of response to cetuximab.
More recently, in patients with KRAS mutations, pani-
tumumab was demonstrated to be ineffective [14], and
therefore this drug was granted approval for the treatment
of patients with wild-type KRAS who have chemotherapy-
refractory CRC. In all the cited studies [8–13], the muta-
tional analysis was conducted almost exclusively on
primary tumors.
It has been shown that primary colorectal tumors may dif-
fer from their corresponding metastases in terms of EGFR [15,
16], Akt, and MAPK protein expression assessed by IHC [17].
While it is well known that KRAS mutations occur in the first
steps of colorectal carcinoma progression [18], additional data
have demonstrated that the frequency of KRAS mutations in
lymph node metastases is higher than in the related primary
CRCs [19]. Because mutations in downstream targets of
EGFR have been shown to correlate with a lesser response to
the EGFR agent cetuximab, assessing this intracellular molec-
ular target might help to predict response to such treatments.
Therefore, it may be of primary importance to verify the cor-
relation between primaries and related metastases with regard
to KRAS status.
The primary endpoint of this study was to verify the
concordance in terms of KRAS status between primary
CRCs and paired metastatic sites.
PATIENTS AND METHODS
Patient Selection
Patients were selected from a pathology database of CRC
cases undergoing surgical resection of the primary tumor
and surgical resection or diagnostic biopsy of the synchro-
nous or metachronous corresponding metastatic site and
collected in the pathology departments of the Azienda
USL6 of Livorno, Università degli Studi di Pisa, Università
Campus Bio-Medico, and Università degli Studi di Palermo
between 1998 and 2007. All these patients had not been, at
the time of specimen collection, treated with any targeted
agents such as cetuximab and panitumumab.
KRAS Mutational Status
We searched for KRAS point mutations in codons 12 and
13, two hotspots that include 95% of mutations in this
gene, as already reported [20].
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Polymerase Chain Reaction Amplification
DNA was extracted from formalin-fixed, paraffin-embed-
ded (FFPE) CRC specimens using the Qiamp DNA FFPE
tissue Kit (Qiagen, Hilden, Germany) according to the man-
ufacturer’s protocol. In total, 25–50 ng of DNA was added
to a volume of 25l with 150M deoxynucleotide triphos-
phates, 6.25 pmol of each primer, 1 U of Hot-Rescue DNA
Polymerase (Diatheva, Fano, Italy), 5% dimethylsulfoxide,
2 mM MgCl2, and 2.5l of 10 polymerase chain reaction
(PCR) buffer. Primers spanned codon 12 and 13 of the
KRAS gene. Primers for the 214-bp amplicon that spanned
exon 2 were 5-GTGTGACATGTTCTAATATAGTCA-3
(forward) and 5-GAATGGTCCTGCACCAGTAA-3 (re-
verse). PCR cycling was run according to the following
conditions: one cycle of 95°C for 10 minutes; 40 cycles of
95°C for 45 seconds, 56°C for 45 seconds, and 72°C for 45
seconds; and one cycle of 72°C for 10 minutes.
DNA Sequencing
PCR products were column purified using the MinElute
PCR Purification Kit (Qiagen) according to the manufac-
turer’s instructions and eluted in a 15-l volume. Con-
centrations were estimated with the ND-1000
Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE).
The cleaned PCR product (10–15 ng) was then used as
a template in cycle sequencing with the BigDye Terminator
v.1.1 CycleSequencing Kit (Applied Biosystems, Foster
City, CA). The reaction mix consisted of 1 l Terminator
ready reaction mix, 1 sequencing buffer, and 3.2 pmol se-
quencing primer in a 20-l total volume.
Two sequencing reactions were performed for each
template with the nested primer 5-GCCTGCTGAAAAT-
GACTGAA-3 (forward) and 5-TGAATTAGCTG-
TATCGTCAAGGCACT-3 (reverse).
Reactions were run according to the following protocol:
one cycle of 96°C for 2 minutes and 40 cycles of 96°C for
10 seconds, 55°C for 5 seconds, and 60°C for 2 minutes.
Sequencing reactions were purified with the DyeEx 96 Kit
(Qiagen) and run on an ABI PRISM 310 Genetic Analyser
(Applied Biosystems). The sense and antisense strands
were aligned and analyzed with Sequence Navigator Soft-
ware (Applied Biosystems).
Statistical Analysis
Considering the primary endpoint, the level of concor-
dance of KRAS status between primaries and related met-
astatic samples was stated at a minimum desirable of
90%, while it was not acceptable at a level80%. Using
the design proposed by A’Hern for the binomial distri-
bution [21], setting the probability of erroneously con-
cluding that the concordance is 80% at 5% (one-sided
 .05) and the probability of correctly concluding that
the concordance is at least 90% at 85% ( 0.15), it was
necessary to perform both evaluations in at least 94 pa-
tients. The minimum number of concordant samples was
set at 82 of 94, because this result is associated with the
lower limit of the 90% confidence interval (CI) of con-
cordance of 80.1%.
RESULTS
We retrospectively analyzed KRAS codon 12 and 13 muta-
tions in primary tumors and related metastatic sites from
107 CRC patients. Eight pairs were excluded from the anal-
ysis because of the low amount of tumor tissue in the avail-
able samples. Ninety-nine patients were available for the
final analysis (Table 1)—50 men (50.5%) and 49 women
(49.5%); median age at diagnosis, 71 years (range, 41–84
years). Thirty-three were affected by right CRC, 46 by left
CRC (including intraperitoneal rectal adenocarcinoma),
and 20 by extraperitoneal rectal cancer. CRC adenocarci-
noma was the unique histotype, and in 10 cases a mucinous
differentiation was detected. Histologic grade 1–2 and
grade 3 were described in 63 (63.6%) and 36 (36.4%) tu-
mors, respectively.
In total, 99 pathologic samples from metastatic sites
were analyzed. The most common site of origin of met-
astatic tissue was the liver, which was noted in 80
(80.8%) cases (synchronous in 75 cases and metachro-
nous in the remaining 24 cases), and the lung, which was
noted in seven cases (metachronous in five cases). The
others organs of tumor origin in the remaining cases are
shown in Table 2.
Table 1. Patient characteristics
Characteristic Value
Total n of patients 99
Age, median (range) 71 (41–84 yrs)
Gender, male/female 50/49
Primary tumor site
Right colon 33
Left colon 46
Rectum 20
Histology
Adenocarcinoma 89
Mucinous differentiation 10
Tumor grade
1–2 63
3 36
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A KRAS mutation was found in 38 (38.4%) primary tu-
mors and in 36 (36.4%) related metastatic sites. The grade
of concordance between primaries and metastatic sites was
96.0% (95% CI, 90.0%–98.9%). Details regarding the fre-
quencies of the different codon 12 and 13 KRAS mutations
in this population are reported in Table 3. All patients, with
the exception of one, with wild-type KRAS primaries also
showed wild-type KRAS metastases. Discordance was ob-
served in only four (4%) patients. In particular, in one pa-
tient KRAS was wild-type in the primary tumor and mutated
in the metastatic site (peritoneum, metachronous); in three
patients KRAS was mutated in the primary tumor and wild-
type in the metastatic site (liver in all three cases, two syn-
chronous and one metachronous).
DISCUSSION
Metastatic CRC represents a major global health prob-
lem, but the introduction of a novel class of targeted an-
tineoplastic agents, mAbs, directed against the EGFR
has significantly changed the therapeutic options avail-
able for these patients. As EGFR targeting provides real
advantages only in a small subgroup of patients, several
attempts have been made to identify predictive factors of
treatment benefit.
Positive IHC staining for EGFR has been used as a cri-
terion for patient selection. All the reported studies, how-
ever, have failed to demonstrate any correlation between
the efficacy of cetuximab and EGFR IHC staining [3, 4].
Nowadays, several retrospective studies have clearly dem-
onstrated the high predictive value of KRAS mutations in
metastatic CRC patients treated with anti-EGFR mAb-
based therapy [8–13]. Because identification of the muta-
tional status of KRAS could help to select patients who have
a high probability of benefiting from anti-EGFR antibodies
[14], it may be of primary importance to verify the degree of
correlation between primaries and related metastases with
regard to KRAS status.
In the present observational analysis, we clearly re-
ported a very high concordance (96.0%; 95% CI, 90.0%–
98.9%) between primaries and related metastases in terms
of KRAS mutational status. A similar grade of concordance
was reported by Molinari et al. [22], who analyzed KRAS
mutational status in a small sample of 30 consecutive pa-
tients with CRC with synchronous or metachronous metas-
tasis. The same mutational pattern between primaries and
corresponding metastases was observed in 26 cases. In
three cases the mutation was restricted to the primary, and
in one case it was restricted to the metastatic lesion, with a
total grade of concordance of 86.6%.
We believe that the data reported in this paper have to be
considered to be of strong clinical impact. Notably, we in-
cluded a very large sample of patients (99 patients) with the
same clinical and pathological characteristics of those in-
cluded in the clinical trials investigating cetuximab- and pa-
nitumumab-based therapies. Furthermore, the prevalence
(36.4%) of KRAS mutations in our sample is similar to that
reported in the literature (about 40%) [5, 6]. We excluded
from the analysis patients with a low amount of available
tumor tissue to avoid false-negative cases derived from the
analysis of the mutational status of normal tissue. In addi-
tion, the mutational status of KRAS was analyzed in a dou-
ble-blinded fashion for each primary and metastatic
sample. In the few cases in which the mutational status was
uncertain, this was interpreted by a third molecular biolo-
gist.
The correlation analysis between the primary cancer
and corresponding metastatic site was discordant in only
four cases. In particular, in one patient KRAS was wild-
type in the primary tumor and mutated in the metastatic
site; in three patients KRAS was mutated in the primary
tumor and wild-type in metastatic site. This high grade of
concordance confirms that KRAS mutation represents a
very early mutational step in CRC pathogenesis and
plays a central role in tumor progression. Indeed, KRAS
mutations are commonly found in patients with CRC and
in the near normal mucosa and, in general, this mutation
Table 2. Sites of metastasis
Site n
Liver 80
Lung 7
Peritoneum 5
Nonregional lymph nodes 1
Bone 2
Local relapse 2
Ovary 2
Table 3. Codon distribution of specific KRAS mutations
Primary
tumor
Metastatic
tissue
G12A 1 1
G12C 3 2
G12D 11 10
G12R 1 1
G12S 2 2
G12V 13 12
G13D 7 8
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might represent an early, stable genetic event that pre-
cedes the appearance of histologically detectable aberra-
tions in colonic epithelial cells [23].
Recent findings underline the importance of a true out-
come predictor for patients with metastatic CRC who are
treated with an anti-EGFR mAb. An improvement in terms
of the response rate and progression-free survival time for
the combination of cetuximab plus chemotherapy versus
chemotherapy alone in the first-line treatment of metastatic
CRC was recently demonstrated in a phase III randomized
trial [24]. In this setting, the vascular endothelial growth
factor (VEGF) inhibitor bevacizumab has already been ap-
proved [25] in combination with irinotecan, fluorouracil,
and leucovorin for the treatment of metastatic CRC. In the
near future, the selection of patients who really benefit from
anti-EGFR mAbs will be even more imperative, especially
for those with metastatic lesions, who are potential candi-
dates for secondary resection in which tumor shrinkage is
the major goal of treatment. For these reasons, future pro-
spective studies may be aimed at evaluating the role of
KRAS mutations in directing the choice of which biologic
(anti-EGFR, anti-VEGF, or both) could be the best partner
for upfront chemotherapy. At the same time, KRAS analysis
may help to avoid unnecessary toxicities and to optimize
the allocation of resources for treating patients in the sec-
ond- or third-line settings. To our knowledge, this is the first
report indicating that the analysis of any available neoplas-
tic tissue (primary or metastatic) for KRAS status is to be
considered adequate and reliable in the vast majority of pa-
tients and this will be of great importance in routine clinical
practice.
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